Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Average Rating of “Moderate Buy” from Brokerages

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $3.3333.

A number of research firms have issued reports on CGTX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Monday, December 29th. B. Riley Financial reiterated a “buy” rating and set a $3.00 target price (up from $2.00) on shares of Cognition Therapeutics in a research report on Friday, November 21st. Brookline Capital Acquisition raised shares of Cognition Therapeutics to a “strong-buy” rating in a report on Tuesday, February 3rd. Finally, HC Wainwright restated a “buy” rating and issued a $3.00 price target on shares of Cognition Therapeutics in a research report on Thursday, December 4th.

Cognition Therapeutics Trading Down 1.0%

NASDAQ:CGTX opened at $1.03 on Monday. The business’s 50-day moving average is $1.23 and its 200 day moving average is $1.58. Cognition Therapeutics has a 12 month low of $0.22 and a 12 month high of $3.83. The company has a market capitalization of $90.92 million, a P/E ratio of -2.15 and a beta of 1.25.

Institutional Trading of Cognition Therapeutics

Large investors have recently made changes to their positions in the business. Raymond James Financial Inc. lifted its holdings in shares of Cognition Therapeutics by 34.7% in the 3rd quarter. Raymond James Financial Inc. now owns 29,641 shares of the company’s stock valued at $40,000 after acquiring an additional 7,641 shares during the last quarter. Bryn Mawr Trust Advisors LLC increased its stake in Cognition Therapeutics by 69.1% during the third quarter. Bryn Mawr Trust Advisors LLC now owns 39,466 shares of the company’s stock worth $53,000 after acquiring an additional 16,129 shares during the last quarter. Jones Financial Companies Lllp purchased a new stake in Cognition Therapeutics during the third quarter valued at approximately $25,000. Essex Financial Services Inc. purchased a new stake in Cognition Therapeutics during the fourth quarter valued at approximately $27,000. Finally, Gamco Investors INC. ET AL bought a new stake in shares of Cognition Therapeutics in the 3rd quarter valued at approximately $27,000. 43.35% of the stock is currently owned by institutional investors.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing disease-modifying therapies for neurodegenerative disorders, with an emphasis on Alzheimer’s disease. The company’s lead investigational candidate, CT1812, is an oral small molecule that antagonizes the sigma-2 receptor complex to protect synapses from amyloid-beta oligomer toxicity. By targeting a novel mechanism of action, Cognition Therapeutics aims to slow or reverse cognitive decline in patients living with Alzheimer’s disease.

CT1812 has successfully completed Phase 1 safety studies and preliminary Phase 2a trials, and is currently being evaluated in multiple Phase 2 clinical studies across North America and Europe in patients with mild-to-moderate Alzheimer’s disease.